The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global botulinum toxin market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum, which is an anaerobic, gram-positive, spore-forming rod commonly found in plants, soil, water, and intestinal tracts of animals. It plays a significant role in the management of a wide variety of medical conditions. These conditions include strabismus and focal dystonia, hemifacial spasm, headaches, hypersalivation, hyperhidrosis, and spastic movement disorders. Moreover, it is utilized in the treatment of various chronic diseases that respond partially to available medical treatments. Nowadays, it is also used for the cosmetic purpose of temporarily reducing frown lines, creases, and wrinkles on the face, chin, neck, and chest.
A significant rise in the prevalence and diagnosis of chronic and acute diseases represents one of the key factors bolstering the market growth. Botulinum toxin finds extensive applications in the treatment of dermatological conditions, such as overactive smooth muscles, abnormal activity of glands, and hyperhidrosis. Moreover, the rising beauty consciousness among individuals, along with their willingness to undergo reconstructive and cosmetic surgeries, is contributing to market growth. In addition, the emerging trend of cosmetic tourism, in confluence with the increasing influence of social media, rapid urbanization, and inflating per capita income, is influencing the market positively. Apart from this, as the skin becomes more susceptible to wrinkles and sagging with age, the growing geriatric population and the desire to retain young and healthy skin are bolstering the market growth. Furthermore, the development of new potent toxins by combining different serotypes can reduce the total units and overall antigenic dose and improve effectiveness and duration of effect. These advancements are projected to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global botulinum toxin market report, along with forecasts at the global, regional and country-level from 2021-2026. Our report has categorized the market based on type, application and end user.
Breakup by Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Eisai Co. Ltd, Evolus Inc, Galderma SA, HUGEL Inc., Ipsen Group, Medytox Inc., Merz Pharma GmbH & Co. KGaA, Metabiologics Inc. and Revance Therapeutics Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Application And End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AbbVie Inc., Eisai Co. Ltd, Evolus Inc, Galderma SA, HUGEL Inc., Ipsen Group, Medytox Inc., Merz Pharma GmbH & Co. KGaA, Metabiologics Inc. and Revance Therapeutics Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at